Novaremed Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 3

Novaremed General Information

Description

Developer of pharmaceutical drugs using small bio-molecules created for the treatment of neuropathic pain. The company develops an orally active non-opioid small molecule with a novel mechanism of action against PDPN which is a tyrosine kinase modulator to be used for the treatment of neuropathic pain, thus enabling doctors and healthcare organizations to effectively treat neuropathy related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Primary Office
  • Teichgaesslein 9
  • 4058 Basel
  • Switzerland

Novaremed Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novaremed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 28-Jan-2021 $50M 000.00 Completed Generating Revenue
7. Later Stage VC 15-Sep-2020 00.000 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 02-Sep-2019 00.000 000.00 000.00 Completed Generating Revenue
5. Later Stage VC 23-Aug-2018 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 17-Apr-2018 00.000 000.00 000.00 Completed Clinical Trials - General
3. Early Stage VC 00.000 00.00 Completed Clinical Trials - General
2. Accelerator/Incubator 23-Jan-2009 $617K $617K Completed Clinical Trials - General
1. Grant 01-Nov-2008 $1.14M Completed Clinical Trials - General
To view Novaremed’s complete valuation and funding history, request access »

Novaremed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 606,452 $0.109923 $10.83 $10.83 1x $10.83 16.83%
Ordinary 453,179 $0.109923 $10.77 $10.77 1x $10.77 12.58%
To view Novaremed’s complete cap table history, request access »

Novaremed Executive Team (8)

Name Title Board Seat Contact Info
Sara Mangialaio Ph.D Chief Marketing Officer, Vice President & Head of Research & Development
Liat Hochman Director, Clinical Operations
Eliahu Kaplan MD Founder, Chief Innovator & Board Member
Nicholas Draeger Chief Executive Officer
Isaac Kobrin MD Executive Chairman
You’re viewing 5 of 8 executive team members. Get the full list »

Novaremed Board Members (13)

Name Representing Role Since
Benyamin Sidon Gefen Biomed Investments Board Member 000 0000
Eliahu Kaplan MD Novaremed Founder, Chief Innovator & Board Member 000 0000
Isaac Kobrin MD Self Executive Chairman 000 0000
Janifer Yeo-Tan Novaremed Board Member 000 0000
Joseph Feinstein Novaremed Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Novaremed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novaremed Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Global Emerging Markets PE/Buyout Minority 000 0000 000000 0
Gefen Biomed Investments Venture Capital Minority 000 0000 000000 0
Biomedix Incubator Accelerator/Incubator Minority 000 0000 000000 0
To view Novaremed’s complete investors history, request access »